Investor Relations


Agile Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability.

0.00 (0.00%)
4:00 PM ET on Dec 7, 2016
Delayed at least 20 minutes.